Abiomed Inc (ABMD)

153.32
1.18 0.78
NASDAQ : Health Care
Prev Close 152.14
Open 152.15
Day Low/High 151.93 / 153.69
52 Wk Low/High 67.81 / 119.90
Volume 307.72K
Avg Volume 307.20K
Exchange NASDAQ
Shares Outstanding 44.10M
Market Cap 6.78B
EPS 1.20
P/E Ratio 90.41
Div & Yield N.A. (N.A)

Latest News

A Roundup of My Open Positions

A Roundup of My Open Positions

Update on the last few Action Alerts Options trades.

Pumped Up About Abiomed Collar Play

Pumped Up About Abiomed Collar Play

The producer of heart pumps also is an interesting name for the longer term.

Abiomed Announces Q1 FY 2018 Revenue Of $132.5 Million, Up 29% Over Prior Year

Abiomed Announces Q1 FY 2018 Revenue Of $132.5 Million, Up 29% Over Prior Year

Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance

Heart Recovery Patients Visit Capitol Hill To Advocate For Lifesaving Cardiovascular Technology

Patients recovered their native hearts with the help of Impella®, the world's smallest heart pump

Abiomed Introduces 3rd Generation Impella CP® Heart Pumps At SCAI 2017

Designed to Enable Ease of Use in High-Risk Percutaneous Coronary Interventions and in the ICU

Abiomed Marks Grand Opening Of Newly-Expanded Headquarters In Danvers, Massachusetts

Governor Baker joins heart recovery leader for grand opening of new manufacturing and training space that represents major investment in Massachusetts

Abiomed's Impella® Technology Showcased At 2017 American College Of Cardiology Scientific Session With More Than 10 Presentations

First Ever Scientific Presentation of Abiomed's Impella® Quality (IQ) Assurance Program

New Study Finds Abiomed Impella® Heart Pump Reduces Injury To Kidneys During High-Risk Percutaneous Coronary Intervention

Circulation Research paper supports previously published randomized clinical trial data

Masimo's Stock Is a Great Buy Right Now

Masimo's Stock Is a Great Buy Right Now

This patient-monitoring device-maker has plenty of room for growth.

Abiomed Surpasses 50,000 Impella® Patients Treated In The United States

Milestone Highlights Significant Unmet Need for Treatment Options Among Advanced Heart Failure Patients

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABMD, ABX, AEM, BGG, BIIB, HBM, HTBI, KALU, MNTA, NEWM, NQ, SNE, VMI, VPG, WMT, XCRA Downgrades: CGNX, DAKT, EXAC, FSLR, HOLI, PFLT Initiations: AGR Read on to get TheStreet Quant Ratings' detailed report:

Abiomed Celebrates 2017 American Heart Month

Leader in heart recovery technology highlights stories of women whose health and quality of life have been improved by Impella® heart pump

Abiomed Announces Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year

Abiomed Announces Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year

Largest Quarterly Sequential Revenue Increase in Company History

Abiomed Announces Preliminary Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year

Abiomed Announces Preliminary Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year

Largest Quarterly Sequential Revenue Increase in Company History

Abiomed Impella CP Receives Expanded FDA Approval For High-Risk Percutaneous Coronary Intervention (PCI) Procedures

Abiomed Impella CP Receives Expanded FDA Approval For High-Risk Percutaneous Coronary Intervention (PCI) Procedures

Impella 2.5, CP and 5.0 Only FDA Approved Percutaneous Heart Pumps Deemed Safe and Effective

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DLR, ESXB, IART, NMR, PBIB, PLNT, SANW, TCK Downgrades: AAN, ABMD, AXTA, CMC, CMPR, CVI, CVRR, DSPG, EHTH, ESSA, FCFS, NPTN, NWS, UHT, VDSI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Abiomed Receives FDA IDE Approval For Initiation Of Door To Unloading (DTU) Prospective Feasibility Study

Abiomed Receives FDA IDE Approval For Initiation Of Door To Unloading (DTU) Prospective Feasibility Study

Study Evaluates the Safety and Feasibility of Unloading of the Left Ventricle with Impella CP® in STEMI Patients, without Cardiogenic Shock